Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior NotesPRNewsWire • 06/26/26
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual MeetingPRNewsWire • 05/27/26
Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/25/26
Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference TranscriptSeeking Alpha • 05/23/26
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung CancerPRNewsWire • 05/13/26
Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)PRNewsWire • 05/07/26
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung CancerPRNewsWire • 05/06/26
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire • 05/04/26
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 04/27/26
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System CancersPRNewsWire • 04/27/26
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026PRNewsWire • 04/21/26
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026PRNewsWire • 04/20/26
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi SankyoPRNewsWire • 04/01/26
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines AgencyPRNewsWire • 03/26/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVBPRNewsWire • 03/26/26
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 03/21/26